MacroGenics amends 8-K to update pro forma financials for CDMO asset sale to Bora Pharmaceuticals

Reuters2026/09/03 20:39

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

MacroGenics filed an amended Form 8-K to restate unaudited pro forma financials tied to its June 30, 2026 CDMO asset sale.
Deal proceeds of USD 119.6 million net were received from Bora Pharmaceuticals, with USD 8.8 million of transaction costs.
Pro forma cash rose by USD 110.81 million to USD 177.32 million as of March 31, 2026.
Estimated gain on derecognition of the sold assets totaled USD 91.71 million, reflected as a reduction in accumulated deficit.
Contract manufacturing revenue and related costs were removed from continuing operations, reflecting the exit from the manufacturing business.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MacroGenics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001125345-26-000059), on September 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

MacroGenics amends 8-K to update pro forma financials for CDMO asset sale to Bora Pharmaceuticals

You may also like

Crypto prices